Comparative Pharmacology
Head-to-head clinical analysis: AXUMIN versus TECHNETIUM TC 99M DIPHOSPHONATE TIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXUMIN versus TECHNETIUM TC 99M DIPHOSPHONATE TIN KIT.
AXUMIN vs TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor; inhibits VEGFR-1, -2, -3, and PDGFR-β, Kit, and RET.
Technetium Tc 99m diphosphonate is a bone-imaging agent that undergoes chemisorption onto hydroxyapatite crystals in bone. Uptake is increased in areas of high bone turnover, such as metastatic lesions, fractures, or inflammation.
AXUMIN (florbetaben F 18) is a diagnostic radiopharmaceutical for PET imaging of beta-amyloid plaques. The recommended dose is 300 MBq (8.1 mCi) administered as a single intravenous bolus injection over 10-15 seconds, followed by a saline flush.
15-30 mCi (555-1110 MBq) IV single dose for bone scintigraphy.
None Documented
None Documented
The terminal elimination half-life is approximately 2.7 hours (range 1.5-5.0 hours) in patients with normal renal function; this supports twice-daily dosing, but may be prolonged in renal impairment.
Terminal elimination half-life: 6–8 hours for the diphosphonate complex; clinical context: allows imaging up to 24 hours post-injection.
Renal elimination of unchanged drug accounts for approximately 60% of the administered dose; fecal excretion accounts for approximately 35% (mainly as unchanged drug); biliary excretion contributes to fecal elimination; less than 1% is excreted in urine as metabolites.
Renal: ~100% via glomerular filtration; no biliary/fecal elimination.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical